Q&A Archives - BioTuesdays

Feature

Titan Pharmaceuticals, UW treating chronic itch with ProNeura implant

As a research assistant professor at the Department of Pharmacology at the University of Washington, Dr. Ben Land, Ph.D. is broadly interested in how cannabinoids and opioids mediate pain and reward. But in a...

November 9, 2021

Feature

Varsha Rao talks up Nurx convenient and affordable care for sensitive health needs

As CEO of closely-held Nurx, the leading female-focused telehealth platform offering patients transparent pricing and judgment-free care, Varsha Rao brings decades of experience balancing mission-driven companies with a...

March 30, 2021

Feature

Keith Sullivan discusses turnaround plan for Neuronetics

As the recently installed president and CEO of Neuronetics (NASDAQ:STIM), a commercial-stage medical device company focused on designing, developing and marketing products that improve the quality of life for patients...

February 23, 2021

Feature

Profound Medical’s TULSA-PRO and Sonalleve treatments at a Center of Excellence at the University Hospital of Cologne

The University Hospital of Cologne is one of the largest in Germany with 59 departments and institutions, and is a leading interdisciplinary Oncology Center of Excellence. Recently, the interdisciplinary uro-oncology...

September 8, 2020

Feature

Profound Medical’s TULSA-PRO prostate cancer treatment finds early adopter in Dr. Joseph Busch

As the founder of Atlanta’s renowned Busch Center, Dr. Joseph Busch Jr. brings a 40-year-plus track record in diagnostic radiology and hundreds of international research studies to preventative screening and accurate...

August 11, 2020

Feature

Seven questions for Ian Koenig of Investis Digital about expediting patient recruitment for clinical trials

In his role as SVP of life sciences, Ian Koenig brings broad experience to Investis Digital in communications strategy, digital marketing, investor relations and business development on behalf of biopharma globally. Mr...

June 9, 2020

Feature

Chris Kaplan of ITG talks up market-making in capital markets

As a VP of Independent Trading Group (ITG), an issuer designated market making firm, Chris Kaplan brings a more institutional approach to provide liquidity for clients with stocks that are thinly traded. ITG, which is...

June 2, 2020

Feature

Dr. Doug Manion of Kleo Pharmaceuticals talks up new approach to treating multiple myeloma

As chairman and CEO of Kleo Pharmaceuticals, a private immuno-oncology company developing next-generation bispecific compounds designed to enhance the activity of biologics, Dr. Doug Manion has a distinguished pedigree...

April 7, 2020

Feature

Amidst a global pandemic, two biotech companies offer innovative solutions

Since COVID-19 was first identified in China late last year, researchers have been working tirelessly to develop diagnostics, therapeutics and vaccines in an effort to prevent the spread of the SARS-CoV-2 virus. Many...

March 31, 2020

Feature

Sebastian Hadjiantoniou of Incuvers discusses accelerating cellular research

As a co-founder and CEO of closely-held Incuvers, an early-stage life sciences company developing a sophisticated incubator for cellular biologists, Sebastian Hadjiantoniou knows firsthand the rocky journey from...

October 1, 2019

Tag - Q&A

Titan Pharmaceuticals, UW treating chronic itch with ProNeura implant

Varsha Rao talks up Nurx convenient and affordable care for sensitive health needs

Keith Sullivan discusses turnaround plan for Neuronetics

Profound Medical’s TULSA-PRO and Sonalleve treatments at a Center of Excellence at the University Hospital of Cologne

Profound Medical’s TULSA-PRO prostate cancer treatment finds early adopter in Dr. Joseph Busch

Seven questions for Ian Koenig of Investis Digital about expediting patient recruitment for clinical trials

Chris Kaplan of ITG talks up market-making in capital markets

Dr. Doug Manion of Kleo Pharmaceuticals talks up new approach to treating multiple myeloma

Amidst a global pandemic, two biotech companies offer innovative solutions

Sebastian Hadjiantoniou of Incuvers discusses accelerating cellular research

General

More